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The Human Glutathione S-Transferase
Supergene Family, Its Polymorphism, and Its
Effects on Susceptibility to Lung Cancer
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David J. Meyer,' Sally E. Pemble,' John B. Taylor,'
Nicholas PR Lang,3 and Fred E Kadlubar4
Cytosolic glutathione S-transferases (GSTs) are a supergene family of dimeric enzymes capable of
detoxifying a number of carcinogenic electrophiles. Of the numerous components of tobacco smoke, the
polycyclic aromatic hydrocarbons appear to be the principal compounds that yield substrates for these
enzymes, GSTM1-1 being effective with those PAH derivatives so far studied; however, the gene locus for
GSTM1 ispolymorphic,containingtwowell-characterized expressinggenes andanullallele.UseofcDNAfor
GSTM1-1 orappropriate fragments ofgenomicclones asprobesinSouthernblotsindicatedthatthenull allele
is due to the absence ofGSTMI. In preliminary experiments, described here, with lung tissue from smokers,
levels of32P-postlabeled nuclease P1-enhanced DNA adducts were inversely correlated with levels ofantigen
cross-reacting with antibody to GSTM1-1, suggesting that initiation depends on the expression ofGSTM1-1.
Since similar quantities of DNA adducts and GSTM1-1 activity have been shown to occur in bronchial and
peripheral lung,however,thedevelopment ofmalignancy, whichisusuallyinthebronchialregion,presumably
depends on additional factors thatbringaboutpromotion andprogression, which are not necessarily affected
by GSTMI expression. Two epidemiological studies have been carried out in which a possible correlation
betweentheabsenceofGSTMI andlungcancerincidence isconsidered. Inthefirst,involvingaU.S.population
sample, smokers with andwithoutlungcancerwerephenotyped, andahighlysignificant correlation between
the absence of GSTM1-1 activity and adenocarcinoma of the lung was observed. In the second, involving
genotyping ofa British population, the correlation between the homozygous GSTMI null genotype and lung
cancer was much less significant and concerned squamous-cell carcinoma.
Introduction
Considerable effort has been put into studies intended
to determine the mechanisms whereby tobacco smoking
brings aboutcarcinogenesis inthelung, butmuch remains
to be learned. The activity of enzymes that toxify and
detoxify carcinogens known to be present in tobacco
smoke has been an important area of study; recently,
genetic polymorphisms in both the cytochrome P450
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CYP2D6 (debrisoquine hydroxylase) (1-3) and one ofthe
glutathione S-transferase isoenzymes (EC 2.5.1.1.18)
(GSTs), GSTM1 [GSTpu/* (4-6)], have been implicated in
susceptibility to the disease. This paper focuses on the
GSTsandexamineswhatisknownoftheirpossiblerolesin
pulmonary and extrapulmonary tissues with respect to
anticarcinogenesis in human lungs exposed to cigarette
smoke.
Glutathione S-Transferases and
Anticarcinogenesis
GSTs are multifunctional proteins that catalyze many
reactions between glutathione (GSH) and lipophilic com-
pounds with electrophilic centers, including those which
are cytotoxic and genotoxic. When the reaction of GSH
with an electrophile forms a stable covalent bond, the
resultant adduct, referred to as a GSH conjugate, is
usuallynolongertoxicandisexcreted.Allcompoundsthat
possess an electrophilic carbon, or acquire onebymetabo-
lism, form adducts by spontaneous reaction, at rates that8KETTERER ET AL.
vary considerably depending on the nature of the elec-
trophilic center (e.g., the second-order rate constant for
thereaction ofGSH atpH 7withthecytotoxinN-acetyl-p-
benzoquinoneimine is 3 x 104 M-1s-1, but that for the
carcinogen metabolite 1-nitropyrene-4,5-oxide is only 0.17
M- ls-1). GSTs catalyze many, but not all, ofthese reac-
tions. These enzymes also catalyze GSH-dependent reac-
tions that do not form stable adducts, such as hydro-
peroxide reduction and certain isomerizations, which
might also be involved in tobacco smoke carcinogenesis
during tumor promotion and tumor progression. These
activities are not discussed in the present papev (7).
Electrophiles such as benzo[a]pyrene (BI )-7,8-diol-
9,10-oxide (BPDE), which react with DNA to produce a
carcinogenic lesion, have a slow spontaneous rate of reac-
tion with GSH; however, if this rate is sufficiently en-
hanced by GST catalysis, the resulting reaction competes
effectively with DNA adduct formation and GSTs are
powerful anticarcinogens (7). The importance of GSH
conjugation in anticarcinogenesis isillustratedbythe case
ofaflatoxin B1 (AFB1) carcinogenesis in rat liver. AFB1 is
metabolized to the electrophile AFB,-8,9-oxide, which
reacts readily with DNA but is poorly conjugated at nor-
mal GSTlevels inthe ratliver,with theresultthatAFB1 is
apowerful rathepatocarcinogen. Inducers ofGST expres-
sion reduce AFB1 binding by DNA to very low levels, and
AFB1-induced carcinogenesis is all but abolished (8). So
far, evidence as direct as this is not available for other
carcinogens: The effect of GSTs on carcinogenesis is
usually inferred from the known enzymic activities of
purified enzymes and knowledge of their cellular con-
centrations.
Glutathione S-Transferase Supergene
Family
In rats and humans, numerous soluble GSTs have been
identified and shown to be dimers, the subunits ofwhich
are members of a supergene family composed of four
multigene families, referred to as a, p,, rr, and 0. The most
extensively studied GSTs arethose oftherat, inwhichfive
a, five ,u, one rr, and two 0 class GST subunits have been
identified bythe combined efforts ofanumber oflaborato-
ries (7). As work progresses, the existence of a similar
multiplicity of forms is becoming apparent among the
human enzymes. The nomenclature is at present very
confusing, but arational systembased onpublished guide-
linesforhuman genenomenclature (9), similartothatused
for the cytochrome P450 supergene family, was devised
recentlyandagreed uponbymanyoftheprincipalworkers
inthefield. This systemisusedinthepresent paper(Table
1).
Manyofthebiologicallysignificantsubstrates forGSTs
are difficult to synthesize, are labile, and are not ideal for
enzymic assay, with the result that the supply of data is
limited. Table 2 shows the values that have been obtained
for BP-4,5-oxide (BPO), the GSH conjugate ofwhich is a
major excretoryproduct ofBP in the rat (10) and perhaps
also in man; +(anti)-BPDE, which is the ultimate car-
cinogenic electrophile derivedfrommetabolism ofBP; and
trans-stilbene oxide, which is used in studies ofGSTM1-1
polymorphisms (7,24).
Distribution of Glutathione
S-Transferase Isoenzymes in Human
Lung and Liver
Tissues vary considerably in overall GST concentration
and also have very specific distributions ofGST subunits.
Such quantitative and qualitative differences between
tissues are presumablyimportantin determiningthe sus-
ceptibility of a tissue to a carcinogen. Tables 3 and 4
address the situation seen in man, in whom the individual
differences can be very great (7). Table 3 shows quantita-
tive values obtained by high-performance liquid chro-
matography (HPLC), using the method of Ostlund
Farrants etal. (25),forexpressionofGST subunitsAl,A2,
and Ml in a number of human liver samples (26). The
absence of GST subunit Ml in a number of cases is
noteworthy. It will be seen below that the GSTM1 null
phenotype occurs in about 50% ofthe population. Table 4
shows the results of quantitative western blotting [for
method, see Towbin et al. (27)] of 11 resected samples of
human lung. Preliminary HPLC analyses indicated that
Al andA2 aredetectedinthe aclassGSTsubunitsMl and
M3 in the ,u class GST subunits, and P1 in the wr class GST
subunit.
Table 1. Nomenclature for human glutathione S-transferases (GSTs).a
Proteins Genes
New Locus
Previous designation forGST Class designation References designation Chromosome References
E,B1Bj, GST2-type 1, Ha (subunit 1),a,at a GSTAl-1 (11-13) GSTA1 6 (12)
8, B2B2, GST2-type2,Ha(subunit2),aoyot a GSTA2-2 (13,14) GSTA2 6 (12)
,u, GST1-type 2, Hb (subunit 4) ,u GSTMla-la (15) GSTM1 1 (15)
*, GST1-type 1 p GSTMlb-lb (4) GSTM1 1 (15)
Muscle, GST4 A GSTM2-2 (16) GSTM2
Brain, GST5 p. GSTM3-3 (17) GSTM3
IT, GST3 Tr GSTP1-1 (18,19) GSTP1 11 (20)
GST 0b 0 (21)
Microsomal GST Microsomal (22) GST12 12 (23)
aFrom B.Mannervik, University ofUppsala, Uppsala, Sweden.
bAvailable dataonamino acid sequencedemonstrateunambiguouslytheexistenceofadistinctclassnamed0,butuntilcompleteprimarystructureis
known it will not be given a designation in the new system (21).
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Table 2. Activities ofhuman glutathione transferases (GSTs)
toward several substrates of importance.
GST BPO BPDE TSO
Containing subunits GSTA1 0.05 ND 0.002
and/or GSTA2
GSTM1-1 0.92 0.69 5.2
GSTM2-2 ND ND ND
GSTM3-3 ND ND ND
GSTPl-1 0.13 2.9 0.002
Abbreviations: BPO,benzo[a]pyrene4,5-oxide (7,24); BPDE, (+)anti-
benzo[a]pyrene-7,8-diol-9,10-oxide (7); TSO, trans-stilbene-oide (24);
ND, not determined.
Figures1Aand1BshowforcomparisontherelativeGST
contents of samples of human liver and lung as demon-
stratedbyHPLC separations. Figure 1CshowstheHPLC
analysis of sufficient of the lung GST protein shown in
Figure1Btoindicatethedetailsofitssubunitcomposition.
Lung Tissue and Lung Cancer
Thetwolobesofthelungbeginattheendofthetrachea,
which divides into two bronchi; each ofthese extends and
furtherdividesintobronchioles,whichundergoincreasing
ramification, ending in the terminal bronchioles, which
open into the mass of alveoli. Proximally, the pseudo-
stratified epithelium ofthe bronchi is lined with flattened
ciliated cells, together with mucus-secreting goblet cells.
Proceeding along the bronchiolar tree, the larger bron-
chioles have a simple columnar epithelium, which is also
ciliated, while the smaller bronchioles have a cuboidal
epitheliumlackingcilia. Finally,inthealveoli,theprincipal
cells aretypes I and IIpneumocytes, theformerproviding
Table 3. Variation in glutathione S-transferase (GST) subunit
and debrisoquine 4-hydroxylase content ofhuman liver.a
Debrisoquine
4-hydroxylase, nmole/
GST subunit, SLg/g liver mg microsomal
Sample Al A2 Ml protein
HL15 94 32 - 0.19
HL16 76 33 - 0.06
HL19 252 37 19 -
HL23 187 25 - 0.09
FH39 300 300 - 0.01
FH41 118 99 - 0.08
FH47 32 150 14 0.05
FH50 149 191 3 0.07
FH56 102 125 42 0.05
FH61 85 385 - 0.03
FH77 404 81 - 0.08
FH80 156 289 - 0.15
FH81 266 277 - 0.10
FH82 93 37 - 0.08
FH83 551 146 - 0.09
FH55 16 47 28 0.01
HL49 99 83 6 -
FH70 76 92 21 -
HL25 125 53 - -
HL62 131 130 14 -
FH84 169 94 - -
HL91 364 333 - -
Mean ± SEM 174.7 ± 28.2 138.1 ± 23.4 18.4 ± 4.4 0.076 ± 0.012
aData from Ketterer et al. (26).
Table 4. Glutathione S-transferase (GST) content of human
adult lung tissue.a
GST subunit, ng/mg pulmonary protein
A1 + A2 M1 + M3 P1
95 24 273
37 62 190
115 97 431
96 174 312
51 nil 273
65 nil 132
41 81 1431
115 327 2117
232 207 2914
19 nil 174
23 19 137
80.8 ± 17.6 89.3 ± 27.8 762 ± 27.9
aNormal tissueobtainedfromlungcancerpatients; GSTsubunitswere
obtainedbyquantitativeWesternblotting(27).ThetiterforGST subunit
M3 is much lower than that for GST subunit Ml.
bMean ± SEM.
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FIGURE 1. Glutathione S-transferase (GST) subunit content ofsamples
ofhuman liver and lung. (A,B) chromatograms obtained using300 ,ugof
tissue protein and (C) a chromatogram obtained using 13.6 mg of the
samelungtissue as shown in Figure 1B. GSTswere analyzedbyaffinity
chromatography followed by high-performance liquid chromatography
according to Ostlund Farrants et al. (25).
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mostofthealveolarsurface, astheyareremarkablythinin
transverse section, and the principal site of gaseous
exchangewiththepulmonarycapillaries. Thevasculariza-
tionofthelunginthisregionismoreextensivethanthatin
any other part ofthe body. TPype I cells are capable ofthe
active pinocytosis of particles that reach their surface,
resulting in their transfer to the interstitium. Both the
interstitium and the lumen of the alveolus contain mac-
rophageswhich engulfmicroorganisms andotherparticu-
lates, such as those derived from tobacco smoke. Those
thatremain intheinterstitium contribute tothe darklung
color seen in smokers, while those that enter the alveolar
lumen (millions per day) pass up and out of the lung by
mucociliary action of the bronchi and upper bronchioles
(28,29).
These arethemajorcellularcomponentsofthelung,but
minor components should not be overlooked, such as the
neuroepithelial APUD (amine uptake and decarboxyla-
tion) cells which accumulate and secrete biogenic amines
and are believed to be the cells oforigin ofsmall-cell lung
carcinoma. Cells of origin for squamous-cell carcinoma
andadenocarcinoma,which arethemostfrequentlyoccur-
ring lung cancers, and ofthe rarer large-cell carcinomas
have not been identified. It is important to note that all
these cancers usually occur in the more proximal parts of
the lung-hence the term bronchiogenic carcinoma. Both
squamous-cell and globlet-cell metaplasia have been
observed in the bronchi of smokers, but whether or not
these are preneoplastic lesions has not been ascertained
(30).
Activation of Carcinogens in the Lung
Although cancerismostlyassociated withthebronchial
region, it cannot be assumed that most carcinogens are
removed and activated in the upper regions of the lungs
and either do notreach the alveoliin sufficient quantity to
be dangerous or are very effectively detoxified there.
Levels of activating enzymes, such as aryl hydrocarbon
hydroxylase and epoxide hydrolase, are presentin similar
amounts in bronchial and alveolar tissue in smokers (31),
and 32P-postlabeling studies on bronchial and alveolar
tissuesfromlungsofsmokers showthatthetworegionsof
the lung have similar levels ofDNA adducts (32).
Bronchoalveolar macrophages are also active in xeno-
biotic metabolism and contain aryl hydrocarbon hydrox-
ylase, epoxide hydrolase, and GST. The macrophages
engulf smoke particulates, which carry adsorbed car-
cinogens such aspolycyclic aromatic hydrocarbons (PAH)
and are capable ofmetabolizing them (33,34). The princi-
palfunctionofthesemacrophagesistoproducebacterioci-
dal (and cytotoxic) oxidizing agents in response to
ingested bacteria; however, other particulates, such as
those found in tobacco smoke, also activate the cytotoxic
activityofmacrophages. Tobacco smokeisalsotoxictothe
cilated epithelium, greatly reducing the effectiveness of
mucociliary clearance ofthe lung. It is possible that, as a
result, the rate of passage of macrophages through the
bronchiisreduced andthattheircytotoxins, togetherwith
some of the carcinogenic metabolites they produce, have
the opportunity to affect the bronchial epithelium (35).
Glutathione S-Transferases of Normal
and Smokers' Lungs
Table 4 shows the GST composition of samples oflung
tissue from a number of adults. In agreement with the
work of Di Ilio et al. (36) and Fryer et al. (37), who
separated native enzymes, GSTPl-1 is the major compo-
nent.OntogeneticstudieshaveshownthatGSTP1-1isvery
dominant atthe earliest stages,whentheprimitive lungis
an invagination of the endoderm and undergoing the
branching associatedwith the growingbronchial tree. As
development proceeds, the level falls steeply and then
remains stable during the rest offetal life, the postnatal
period, andadultlife(thelungisvascularizedearlyinfetal
life).Theacclassenzymesoccuratlowlevelsthroughoutall
stages ofdevelopment, and GSTM1-1 occurs atevenlower
levels in those individuals in whom it is expressed. The
studies in which these findings were made were done
before GSTM3-3 and other members of the ,u family
(apartfrom GSTM1-1) had been isolated and identified.
Preparations of bronchial and peripheral tissue from
adults have similar BPO-GST activities (31). Smoking
causes a small but significant depression in BPO-GST
activity in lung tissue overall (38), but bronchiolar mac-
rophages undergo a considerable reduction (34).
Relationship between Level of
DNA Adducts and Glutathione
S-Transferase Contentofthe
Lungs of Smokers
Althoughtheproperties andtissue distribution ofGSTs
have been described, it is unclear how they might affect
detoxication of the many components of tobacco smoke
that have been shown to be carcinogenic and that may be
involved in the etiology ofsmoking-induced lungcancer. A
list of some of the carcinogens known to be present in
cigarette smokeincludesPAH,nitrosamines, andaromatic
amines(35).Sofar,onlyPAHmetaboliteshavebeenshown
to be substrates for GSTs. Thus, the assays for BPO-GST
activity described above are relevant forhumans (and are
believed to be important in rats) (10), to the extent that
BPO-GSH conjugation is an important pathway of BP
detoxication. BPO is known to be a good substrate for
GSTM1-1, less so for GSTP1-1, and even less so for GSTs
containingAl and A2. (+) anti-BPDE, however, which is
known to be the ultimate carcinogen in some tissues (e.g.,
skin), is agood substrate forGSTM1-1, and an evenbetter
one for GSTPl-1, which not only results in higher rates
thanotherGSTsbutismore selectiveforthemetabolically
produced (+) anti-enantiomer (7). Unfortunately, no data
are available on GSTM3-3 and other ,u-class enzymes.
Since the GSTs Mi-1 and P1-1 are known to catalyze the
detoxication ofPAHinvitro, onemightexpectto see some
effect of GSTs on PAH-DNA adduct levels in smokers.
Figure 2 shows a comparison between the levels of
nuclease P1-enhanced 32P-postlabeled DNA adducts [see
the method described in Talaska et al. (39)] and of GST
subunitsMi + M3insmokersandnonsmokers.These are
preliminary results; nevertheless, there appears to be an
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FIGURE 2. Relationship in the lungs ofsmokers between levels ofnucle-
ase P1-enhanced 32P-postlabeled DNA adducts and of antigen cross-
reactingwiththeantibodytoGSTM1-1 (which mayalsohave alowlevelof
cross-reactivity with GSTM3-3). The method for 32P-postlabeling and
quantitative immunodetection using 131I-labeled antibody are described
by Towbin et al. (27) and Talaska et al. (39), respectively.
inverse correlation. No correlation was seen with GST
subunits Al + A2 or P1.
Aproportion ofthe smokethatenters thelungsistaken
up by the epithelium during its passage down the bron-
chiolar tree, but the remainder gains ready access to the
bloodstream in the alveoli. Figure 1 shows that the detox-
ication capacity ofthelungis verymuch lowerthan thatof
theliverandperhaps ofotherextrapulmonarytissues.The
same is true of the activating enzymes (30). The conse-
quence is that tobacco smoke produces DNA adducts not
only in lung tissue but also in a number of extrahepatic
tissues, ranging from those most immediately accessible,
such as the heart, to those more distant, such as the liver
and kidney (40). Table 2 shows that little effect of GSTs
containing subunits Al and/or A2 is to be expected; even
the major component GSTPl-1 occurs at low levels com-
pared to the levels of GSTs found in the liver. Products
derived from tobacco thatreach theblood mayrecirculate
and be further metabolized by the lung, but their amount
will be considerably reduced and they will be changed
qualitatively after passage through the liver. It may be
thatthe adducts that arefoundinthelungdepend notonly
on the metabolism ofinhaled aerosol entering tissue from
the lumen but also on the activation ofprogenotoxins (e.g.,
BP-7,8-diol, 9-OH-BP) entering lung tissue from the
bloodstream. Levels of extrapulmonary PAH and PAH
derivatives may be affected profoundly bywhether or not
GSTM1-1 isexpressedintheliver, sincecytochrome P450s
are inhibited by the products of their action. GST and
epoxide hydrolase have important functions in removing
these inhibitors (10). The results shown in Table 3 might
then be the result ofthe combined effects ofprimary and
secondary pulmonary metabolism, the latter being most
importantin theperipheral lungwheretheblood supplyis
so rich. It should be noted, however, that, regardless of
their origin, the levels of DNA adducts are similar in the
bronchial andperipheralregions ofthelungalthough lung
cancer is much more common in the bronchi.
Relationship between Lung Cancer
and Glutathione S-Transferase
Genotype
Evidence has been given that DNA adduct formation is
inversely correlated with the GST ,u-class phenotype and
there may be a similar correlation with susceptibility to
lung cancer. Thus, Seidegard and his colleagues (4,5,24)
have demonstrated a significant correlation between the
occurrence of carcinoma of the lung and low levels of
trans-stilbene oxide-GSH transferase activity in blood
leukocytes, this compound having been shown to be a
particularly good substrate for GSTM1-1 (Table 2). They
compared smokers with and without lung cancer and
found thattheGSTM1 nullphenotype was associatedwith
susceptibility to lung cancer and that this association was
highly significant in patients with adenocarcinoma (Table
5). UsingSouthernblots ofDNAobtainedfromblood cells,
probed with subunit GSTMlb cDNA, they compared phe-
notype with genotype in a handful of cases and showed
that the GSTM1 null phenotype was associated with a
deletion; thus, in the GSTM1*O/GSTM1*O genotype, the
GSTM1 gene is partly ortotally absent (5).
In this particular population sample, studied by phe-
notyping, there was apreponderance ofadenocarcinomas,
which is regarded as not typical. Squamous-cell car-
cinomas are the commonest among smokers in western
society, although adenocarcinomas appear to be on the
increase (30). In a recent study by Zhong et al. (6),
involving genotyping rather than phenotyping, in which
probes were derived from highly conserved regions of ,u
family genomic DNA (41), the correlation between
GSTM1*0/GSTM1*0 and adenocarcinoma was, if any-
thing, negative. There was, however, a small but positive
correlation of GSTM1*O/GSTM1*O with squamous-cell
carcinoma. This population had the more usual prepon-
derance of squamous cell carcinomas (Table 6) (30). The
discrepancybetweenthe results ofthesetwo studiesis not
yetunderstood.
Some ,u-class genes are clustered. The remarkable
conservation in genomic structure in both exons and
regions of introns which has been shown in this family
shows that gene conversion has occurred and should con-
tinue to do so (41). A situation can be envisaged in which a
gene conversion gives a positive genotype but a null phe-
notype, because a conversion event has occurred, and
results in a negative regulatory effect on the gene. Such a
¶Ible 5. Association between risk for lung cancer among smokers
and the GSTM1 null phenotype.a
Subjects GSTM1-1/GSTM1 null p-Value
Smokers
Small-cell carcinoma 3/12 0.02
Large-cell carcinoma 4/10 0.25
Squamous-cell carcinoma 27/62 0.04
Adenocarcinoma 28/93 0.0001
Other 8/14 0.93
Total 70/191 0.001
Controls 112/192
aData from Seidegard et al. (5).
Ip=0.041
0
*"% 0~~~~~~~~~
0 a I Ir
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lable 6. Proportion ofGSTMI*OIGSTMJ*O in individuals with and without lung cancer.a
Squamous-cell
All controls All lung cancers" carcinomac Adenocarcinomad Otherlung cancerse
Genotype (225) (228) (100) (56) (72)
GSTMi*O/GSTM1*0 58% (131) 57% (130) 52% (52) 29% (16) 58% (42)
GSTM1 detected 42% (94) 43% (98) 48% (48) 71% (40) 42% (30)
aData from Zhong et al. (6); figures in parentheses indicate numbers ofindividuals tested in each category.
bControls/all lung cancers: -2 = 0.07; p = 0.85.
'Controls/squamous-cell carcinomas: '2 = 2.92; p = 0.09.
dControls/adenocarcinomas: -2 = 3.28; p = 0.07.
eControls/other lung cancers: *2 = 0.02; p = 0.99.
hybrid would not have the GSTM1*O-associated deletion
or ever give rise to a GSTM1*O/GSTM1*O genotype;
however, such gene conversions would not be ofsufficient
frequency to explain the discrepancy between the results
ofSeidegardetal. (5) andthoseofZhongetal(6),although
theycouldexplain occasionalinconsistenciesbetweengen-
otype and phenotype. One should also be aware that
genotyping by polymerase chain reaction ofmembers of
the GST , multigene family,which has such ahighlevel of
sequence identity in introns and exons arising from gene
conversion, mayresultin an artefactuallypositive attribu-
tion ofgenotype.
Discussion
The lung has the capacity to activate and detoxify BP,
and presumably other PAHs, in both the bronchiolar and
alveolarepithelia(31),butthelevelsofmanyactivatingand
detoxifying enzymes in this organ are low overall, and a
significant proportion of the PAH load that a tobacco
smoker encounters maypass into the systemicbloodtobe
toxified and detoxified in extrapulmonary tissues (40).
Among the members of the GST supergene family for
which the specificity toward some substrates is known,
GSTM1-1 is effective with both apresumed major epoxide
metabolite of BP, namely BPO, and the ultimate car-
cinogen BPDE (7) and is therefore important for their
detoxication and excretion. (The activities of the GSTs
M2-2 and M3-3 with these substrates have yet to be
determined, and the activities towards other electrophilic
substrates such as BP-7,8-oxide are not known.) Even so,
theimportance ofthe ,ufamilyforthe detoxication ofPAH
is borne out by our preliminary experiments in which the
level of immunochemically determined ,L family GSTs in
the lungs of smokers appears to be inversely correlated
with its nuclease-Pi 32P-postlabeled DNA adducts. The
GSTM1 locus is polymorphic and has a null allele that
occurs atsuchfrequencythatGSTM1 nullphenotypes are
present in appoximately 50% of the population (4-6,40).
Individuals with null phenotypes are expected to have
reduced abilities to detoxify BPO and BPDE. Thus, the
expression of GSTM1-1 could affect the development of
PAH-dependent cancer; this should be apparent when
eitherthe GSTM1-1phenotype orthe GSTM1 genotype is
determined.
It should be noted that, in the two studiesperformed so
far, the analysis of phenotype has shown much more
significantcorrelations than studies ofthegenotype (4-6).
This might be due to the differentepidemiological designs
of the two studies, to the different origins of the two
populations studied (thephenotyping havingbeen done on
a U.S. group and the genotyping on aBritish group), orto
other undetermined factors. It should be borne in mind
that atleast one othergenetic polymorphismis associated
with lung cancer, namely that involving the debrisoquine
hydroxylase (CYP2D6) locus (1-3). There is no linkage
with the GSTM1 polymorphism, with the result that the
effect ofone may either obscure or enhance the effects of
the other or be neutral, according to inheritance. Simul-
taneousgenotypingofthesameindividualsfortheGSTM1
deletion and CYP2D6 mutants might reveal populations
with very significant differences in susceptibility to lung
cancer. A glance at Table 3 shows individuals in which
GSTM1 and debrisoquine hydroxylase expression might
workwith each other (HL15, FH80) oragainst each other
(FH55) to promote susceptibility to lung cancer.
Since the levels ofGSTs, including GST subunit Ml, in
the lung are low (Fig. 1), a significant proportion of the
detoxication ofPAH from tobacco smoke may occurin the
extrapulmonarytissue and some DNAdamageinthelung
may be secondary, due to bloodborne progenotoxic PAH
metabolites released from other organs.
Datacurrentlyavailable donotexplainwhylungtumors
are mostly associated with the bronchi rather than with
the alveoli, to which PAH are similarly accessible.
Unknown but critical promotion events may occur in the
bronchuswhich donotoccurmore distally. Inthis respect,
bronchoalveolarmacrophagesmayplayarole: notonlyare
theirlevels ofBPO-GST sharplyreduced bysmoking (34),
buttheymayalso spendmoretimeinthebronchial areaof
smokers, since mucociliary action is inhibited by tobacco
smoke(35).Wherevertheyare,theyproducenotonlyPAH
metabolites but also cytotoxic active oxygen, which is a
promoterinthe skin andperhaps alsointhelung[see also
Kadlubar et al. (42)].
This manuscript was presented at the Conference on Biomonitoring
and Susceptibility Markers in Human Cancer:Applications in Molecular
Epidemiology and Risk Assessment that was held in Kailua-Kona,
Hawaii, 26 October-1 November 1991.
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manuscript.
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